Viking Therapeutics: The Long View
What the filings say about its story, dilution and cash runway.
Disclosure: one or more of our editors own shares of Viking Therapeutics (VKTX) as a long-term investment. This page is information, not investment advice.
Sources used most:
- 10-K FY2025, filed Feb 11, 2026
- 10-Q Q2 2026, filed Jul 29, 2026
- Q2 2026 results release, Jul 29, 2026
- Q3 2026 results release, Oct 28, 2026 (8-K)
- 10-Q Q3 2026, filed Oct 29, 2026
- 8-K on the September 2026 share and convertible-note offerings, filed Sep 28, 2026
1. In one paragraph
Last updated Oct 29, 2026. Reflects the 10-K FY2025, the 10-Qs for Q2 and Q3 2026 and company releases through the Q3 2026 results release (Oct 28, 2026).
Viking is a clinical-stage drug developer in San Diego with no products on sale and no revenue, so its spending is funded by money it raises, not by customers. Its lead drug, VK2735, is in Phase 3.
- Business: no products on sale, never any revenue, one segment (10-Q Q2 2026).
- Lead drug: VK2735 activates two gut-hormone receptors, GLP-1 and GIP, the same pair targeted by Eli Lilly’s tirzepatide (Zepbound). Viking owns it outright.
- Weekly injection: now in two Phase 3 trials (large trials intended to support approval) for obesity.
- Daily tablet: its Phase 3 programme began in October 2026.
- Behind it: VK3019, an amylin-type obesity drug in Phase 1 (an early safety trial), and older programmes licensed from Ligand Pharmaceuticals: VK2809 and VK0214 (both subject to a licence dispute) and VK5211, which Viking intends to partner or license out.
- 2025 costs: $393.3M of operating expenses, made up of research and development $345.0M (88%) and general and administrative $48.4M (12%). Interest income of $33.7M brought the net loss to $359.6M (10-K FY2025).
- Viking does not track R&D spending by programme. It had 53 full-time employees at Dec 31, 2025 and 65 at Jun 30, 2026.
2. Story so far
Last updated Oct 28, 2026. Reflects filings and releases through Oct 28, 2026.
In short: Viking began as a licensee of Ligand drug programmes, but since 2023 its story has been VK2735, which it discovered itself. Mid-stage data in February 2024 more than doubled the share price and funded a $632.5M share sale; the injection entered Phase 3 in June 2025, while the tablet’s mid-stage data in August 2025 were followed by a 42% one-day fall. In September 2026 Viking reported maintenance-dosing data and raised $575.0M gross from new shares and convertible notes (debt that can convert into shares or be settled in cash under specified terms); Ligand is disputing Viking’s rights to the older VK2809 programme.
| Date | Milestone | Source |
|---|---|---|
| May 21, 2014 | Signs the Master License Agreement with Ligand for VK2809, VK0214, VK5211 and other programmes | 10-Q Q2 2026, MD&A |
| Mar 28, 2023 | Phase 1 VK2735 injection data: up to 7.8% weight loss from baseline (6.0 percentage points more weight loss than placebo) after 28 days | Release |
| Apr 2023 | Sells 19.83M shares at $14.50 ($287.5M gross) | 10-K FY2025, equity note |
| Feb 27, 2024 | ★ Phase 2 VENTURE: up to 14.7% weight loss from baseline (13.1% placebo-adjusted) after 13 weekly injections. Yahoo Finance reports a close of $85.05, up 121% from $38.48 the day before | Release; Yahoo Finance |
| Feb 28–Mar 4, 2024 | Sells 7.44M shares at $85.00 ($632.5M gross, our calculation)1, including 2.19M shares from treasury | Pricing release; 10-K FY2025 |
| Mar 10, 2025 | Signs multi-year manufacturing agreements with CordenPharma for VK2735, with prepayments totalling $150M over 2025–2028 | Release |
| May 29, 2025 | The US International Trade Commission affirms most of a ruling that Ascletis misappropriated Viking’s trade secrets; both sides later appealed | 10-Q Q2 2026, legal proceedings |
| Jun 23, 2025 | ★ Phase 3 VANQUISH-1 (obesity, about 4,500 patients) and VANQUISH-2 (obesity with type 2 diabetes, about 1,000) start; 78 weeks of weekly injections | ClinicalTrials.gov NCT07104500; Q2 release |
| Aug 19, 2025 | ★ Phase 2 tablet data: up to 12.2% weight loss from baseline after 13 weeks (placebo 1.3%). Yahoo Finance reports a close of $24.36, down 42% from $42.09 | Release; Yahoo Finance |
| Nov 2025 / Q1 2026 | VANQUISH-1 fully enrolled (about five months after start); VANQUISH-2 fully enrolled in Q1 2026 | Q2 release |
| Apr 24, 2026 | Ligand notifies Viking that it is terminating Viking’s licence to the thyroid hormone receptor beta (TR-β) programme (VK2809, VK0214); Ligand sues on May 19 and Viking cross-complains on Jul 2 | 10-Q Q2 2026 |
| Jul 29–30, 2026 | Ends its old at-the-market share-sale programme and signs a new one on Jul 29; the replacement $500M, three-year buyback (replacing an unused $250M programme) becomes effective Jul 30 | 10-Q Q2 2026, Part II, Item 5 |
| Sep 22–25, 2026 | ★ Maintenance study: 16–19% weight loss after 21 weekly injections; switching to every-other-week dosing kept up to 97% of the loss over 12 weeks and monthly dosing up to 90% (placebo 61%). Yahoo Finance reports a close of $40.85, up 36% from $30.11. Then, on Sep 23–25, it sold 9.04M shares at $35.00 ($316.25M gross) and $258.75M of 2.00% convertible notes due 2032, including both over-allotment options | Release; Yahoo Finance; 8-K |
| Oct 14, 2026 | Starts the SUNRISE Phase 3 programme for the tablet: two 68-week trials of 560 adults each | Release |
| Oct 28, 2026 | Q3 2026: net loss of $183.2M as R&D rose to $166.8M; cash, cash equivalents and short-term investments of $960M after the September raises | Q3 release |
| Oct 28, 2026 | Start of our coverage: this Long View | — |
3. Latest quarter: did the story change?
Last updated Oct 29, 2026. Reflects Q3 2026 (results release, 8-K filed Oct 28, 2026, and the 10-Q filed Oct 29, 2026).
Bottom line: Spending rose sharply in Q3 as more trials ran and drug manufacturing grew, so the quarterly loss widened by about 43%; the September share and note sales lifted cash to $960M, and Viking now says its cash gives it the runway to complete its Phase 3 obesity trials.
| Driver | Last quarter → this quarter | Management: before → now | Signal |
|---|---|---|---|
| Spending and net loss | R&D Q2 $115.8M → Q3 $166.8M; general and administrative $16.8M → $20.3M; net loss −$128.0M → −$183.2M | No financial guidance. Viking attributed the rise from Q3 2025 to clinical studies, manufacturing, stock pay, salaries and consultants (Q3 release) | Worse |
| Cash and runway | Cash and investments, excluding restricted cash, $501.7M (Jun 30) → $960M (Sep 30), including about $550M of net proceeds from the September offerings; operating cash use Q2 $125.2M (our calculation)2 → Q3 $138.2M (our calculation)3 | Cash to last “through at least September 30, 2027” (10-Q, Jul 29, before the raises) → runway to reach milestones “including completion of the company’s ongoing Phase 3 obesity trials” (Oct 28); the Q3 10-Q now says “through at least December 31, 2027” | Better |
| VANQUISH Phase 3 (injection) | Fully enrolled → “continue to advance on track” | “Proceeding according to plan” (Jul 29) → completion expected in 2027; extension studies to start in 1Q27, with results expected in 2028 (Oct 28) | Unchanged |
| Tablet and maintenance programmes | Planned → SUNRISE Phase 3 initiated (Oct 14); maintenance study Part 2 initiated (Oct 6) | Tablet Phase 3 “expected 4Q26” (Jul 29) → initiated Oct 14, 2026; Part 2 results expected in 2027 (Oct 28) | Unchanged |
| VK3019 (amylin-type drug) | Phase 1 single-dose study started → “nearing completion” | Phase 1 “underway” (Jul 29) → single-dose study to finish in Q4 2026 and a 4-week multiple-dose study to start in 1Q27 (Oct 28) | Unchanged |
Unresolved questions: the schedule of the remaining CordenPharma prepayments (the Q3 10-Q repeats that they are paid over 2026–2028, without amounts by period); the outcome of the Ligand demurrer (hearing Feb 26, 2027); whether Q3’s higher spending is the new run-rate.
4. Buybacks vs real dilution (5 years)
Last updated Oct 29, 2026. Reflects the equity statements in the 10-K FY2022, 10-K FY2025 and 10-Qs Q2 and Q3 2026, and the September 2026 offering documents.
Dilution in one line: shares outstanding rose 63% from Dec 31, 2021 to Sep 30, 2026, about 10.8% a year compounded. If you owned 1% of Viking at the end of 2021, you would have owned about 0.61% on Sep 30, 2026 without buying more (our calculation)4. Buybacks offset about 4% of the new shares issued. Our scale: High (over 3% a year).
Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.
Change in the period Total since Dec 31, 2021 Part year
Shares outstanding at period end (all classes): 78.2M on Dec 31, 2021, 127.5M on Sep 30, 2026, +63.0% (our calculation). A bar below zero means the count fell (net buybacks).
Shares outstanding (one class), from the author's bridge (10-K and 10-Q equity statements).
| Period end | Shares outstanding | Change | Buybacks (fiscal year) | Stock-based pay (fiscal year) | Stock pay as % of revenue |
|---|---|---|---|---|---|
| 9M 2026 (Sep 30, 2026) | 127.5M | +11.1% | — | — | — |
| FY2025 (Dec 31, 2025) | 114.8M | +2.9% | — | $41M | — |
| FY2024 (Dec 31, 2024) | 111.6M | +11.5% | — | $30M | — |
| FY2023 (Dec 31, 2023) | 100.1M | +27.8% | — | $17M | — |
| FY2022 (Dec 31, 2022) | 78.3M | +0.1% | $7M | $9M | — |
| FY2021 (Dec 31, 2021) | 78.2M | — | — | $6M | — |
Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.
Share sales for cash were the largest source of new shares; the only buybacks were in 2022 (2.2M shares).
Show the data
| Label | Underwritten sales | At-the-market sales | Stock pay and warrants | Unit |
|---|---|---|---|---|
| 2022 | 0 | 1.4 | 0.8 | M shares |
| 2023 | 19.8 | 0.2 | 1.9 | M shares |
| 2024 | 7.4 | 1.4 | 2.6 | M shares |
| 2025 | 0 | 2.1 | 1.1 | M shares |
| H1 2026 | 0 | 1.0 | 0.8 | M shares |
| Q3 2026 | 9.0 | 1.5 | 0.4 | M shares |
Chart source5.
How we calculated this
Viking has one class of stock.
| Bridge (millions of shares) | 2022 | 2023 | 2024 | 2025 | H1 2026 | Q3 2026 | Total |
|---|---|---|---|---|---|---|---|
| Start of period | 78.2 | 78.3 | 100.1 | 111.6 | 114.8 | 116.7 | 78.2 |
| Underwritten share sales | – | 19.8 | 7.4 | – | – | 9.0 | 36.3 |
| At-the-market share sales | 1.4 | 0.2 | 1.4 | 2.1 | 1.0 | 1.5 | 7.7 |
| Stock pay and employee plans (net of shares withheld for taxes) | 0.3 | 1.9 | 2.6 | 1.1 | 0.8 | 0.4 | 7.0 |
| Warrants exercised (rights to buy shares at a specified price) | 0.5 | – | – | – | – | – | 0.5 |
| Buybacks | −2.2 | 0 | 0 | 0 | 0 | 0 | −2.2 |
| End of period | 78.3 | 100.1 | 111.6 | 114.8 | 116.7 | 127.5 | 127.5 |
-
Totals use unrounded filing figures.
-
The 2.19M repurchased shares were held in treasury and re-sold in the March 2024 offering; they are counted as a buyback in 2022 and as part of the 7.44M shares sold in 2024 (10-K FY2025, equity note).
-
Viking withheld 1.27M shares from employees to cover taxes in 2022–2024 and none in 2025 or H1 2026; the company does not count these as buybacks, and they are netted in the stock-pay row.
-
Q3 2026: Viking sold 1.48M at-the-market shares (Aug 5–Sep 14) and 9.04M offering shares (424B5, 8-K), and issued 0.29M shares to three executives when performance stock units vested on Jul 28, 2026 (Forms 4 filed Jul 29, 2026: CEO 221,667, CFO 31,667, COO 31,667). The Q3 release reports 127,521,229 shares at Sep 30, 2026. The remaining Q3 increase is about 0.07M shares (our calculation)6; its source is not confirmed until the Q3 equity statement is filed, and we provisionally group it with employee-plan issuance in the bridge and chart. The Q3 10-Q will give the full equity statement.
-
The convertible notes convert at 19.7044 shares per $1,000, an initial conversion price of about $50.75, or about 5.10M shares in total (our calculation)6. Viking may settle conversions in cash, shares or both, and a takeover or early redemption can raise the conversion rate (8-K).
Prices paid and received:
| Period | Shares bought back | Average price paid | Spent | Shares sold for cash | Average price received | Raised | Sources |
|---|---|---|---|---|---|---|---|
| 2022 | 2.19M | $3.10 (our calculation)7 | $6.8M | 1.41M | Gross average not separately disclosed | $11.7M net; gross not separately disclosed | 10-K FY2022, equity and cash flow statements (at-the-market sales) |
| 2023 | — | — | — | 20.01M | Underwritten: $14.50; combined gross average not separately disclosed | $287.5M underwritten gross plus $2.0M at-the-market net | 10-K FY2025: 19.83M shares at $14.50; 0.18M at-the-market shares |
| 2024 | — | — | — | 8.87M | ≈$76.75 (our calculation)7 | ≈$680.6M gross | 10-K FY2025: 7.44M shares at $85.00; 1.43M at-the-market shares; 10-K FY2024 |
| 2025 | — | — | — | 2.13M | ≈$35.76 (our calculation)7 | ≈$76.2M gross | 10-K FY2025: at-the-market sales ($73.9M net) |
| 2026 to date (Jan 1–Sep 25) | — | — | — | 11.55M | ≈$34.79 (our calculation)7 | ≈$401.8M gross | 10-Q Q2 2026: H1 1.03M at-the-market shares ($34.2M net); 424B5, Sep 25: 1.48M at-the-market shares Aug 5–Sep 14; 8-K, Sep 28: 9.04M shares at $35.00 ($316.25M gross) |
Prices are per share; Viking has made no stock split in the period. Raised is gross proceeds before commissions and costs; averages and gross at-the-market amounts are (our calculation)7. For 2022 and 2023 only net at-the-market proceeds are disclosed, so no combined gross average is shown. Not counted as sales for cash:
- employee option exercises and share-purchase-plan sales;
- the 2022 warrant exercises (0.49M shares, $0.6M);
- the $258.75M of 2.00% convertible notes sold on Sep 25, 2026, which are debt until converted.
For reference, Yahoo Finance reports a closing price of $24.89 on Oct 27, 2026 (historical prices).
Granted options and units, plus unused sales capacity, could still add shares; the $500M buyback authorisation has not been used.
Share claims and programme capacity
- At Jun 30, 2026, options on 5.99M shares (average exercise price $17.83) and 1.81M restricted stock units (awards that deliver shares when vesting conditions are met) were outstanding, and 9.48M shares remained reserved for future awards under the 2024 equity plan (424B5).
- $449.8M remained available under the at-the-market programme as of Sep 30, 2026, and no shares were repurchased under the $500M buyback approved in July 2026 (10-Q Q3 2026).
| Stock-based pay | 2022 | 2023 | 2024 | 2025 | H1 2026 |
|---|---|---|---|---|---|
| $M | 8.7 | 16.8 | 29.7 | 40.8 | 21.5 |
| % of operating expenses (our calculation)8 (Viking has no revenue) | 12% | 17% | 20% | 10% | 7% |
5. Profit vs cash (latest FY and TTM)
Last updated Oct 29, 2026. Reflects the 10-K FY2025, the 10-Q Q3 2026 (with Q3 2025 comparatives), the 10-Q Q3 2025, the September 2026 offering documents and the Q3 2026 results release. Viking reports no adjusted profit measure.
Viking’s cash outflow has been smaller than its net loss, mainly because stock pay is non-cash and unpaid bills to suppliers and trial sites rose. Viking reported no capital spending in 2025 or the first nine months of 2026, so free cash flow equals operating cash flow.
| $M | FY2025 | Trailing twelve months (TTM) to Sep 30, 2026 (our calculation)9 |
|---|---|---|
| Net loss | −359.6 | −627.2 |
| Adjusted metric | Not reported | Not reported |
| Operating cash flow | −278.7 | −462.6 |
| Capital spending | 0.0 | 0.0 |
| Free cash flow (our calculation)9 | −278.7 | −462.6 |
Q3 2026 alone: net loss $183.2M, operating cash use $138.2M (our calculation)3.
Some of the gap reverses in later periods, so it is worth sorting the reconciling items by what they do next:
Helps future profit or cash:
- Interest accrued on discounted short-term investments ($9.3M in 2025): counted in the loss now, with the cash arriving at maturity.
Hurts future profit or cash:
- Prepaid expenses ($5.2M of cash in 2025, $3.4M in the first nine months of 2026): cash was paid before the expense was recognised. Recognising that expense later increases the loss without another cash payment.
- Higher payables and accrued costs ($49.6M in 2025, $56.6M in the first nine months of 2026): cash that was kept for now goes out when the bills are paid.
- Stock-based pay ($40.8M in 2025): a recurring cost that lowers reported profit; it is added back as a non-cash expense and shows up as new shares (dilution) instead (see section 4).
One-off / no lasting effect:
- None among the biggest items.
The raw reconciling items
- Stock-based pay added back $40.8M in 2025 ($47.9M TTM, our calculation)9.
- Higher payables and accrued costs kept $49.6M of cash in 2025 ($43.4M payables, $6.2M accrued expenses) and $56.6M in the first nine months of 2026 ($28.9M and $27.7M). This cash will go out when the bills are paid.
- Interest accrued on discounted short-term investments ($9.3M in 2025) is counted in the loss before the cash arrives at maturity.
- Prepaid expenses used $5.2M of cash in 2025 and $3.4M in the first nine months of 2026.
Funding: how long without new money? (as of Sep 30, 2026) At the past year’s free cash outflow ($462.6M), Sep 30 cash of $959.8M covers about 2.1 years (our calculation)10; no debt is due within 24 months and no credit lines are disclosed.
Funding details
- Cash, cash equivalents and short-term investments: $959.8M at Sep 30, 2026 ($677.6M cash and equivalents plus $282.2M investments; the release rounds this to $960M and excludes $0.2M of restricted cash). It includes about $550M of net proceeds from the September offerings (Q3 release). Trailing-12-month free cash outflow was $462.6M (our calculation, 10-Q Q3 2026)11.
- Viking’s own statement (Oct 28): the cash provides “the runway needed to reach important milestones, including completion of the company’s ongoing Phase 3 obesity trials”, which it expects in 2027, and supports its growing commercial operations (Q3 release). Its Q3 10-Q (Oct 29) says cash will fund operations “through at least December 31, 2027” (10-Q Q3 2026); before the raises, the Q2 10-Q said “through at least September 30, 2027” (10-Q Q2 2026). Viking expects losses to “increase materially” as it develops VK2735 and seeks approval.
- This is based on past cash flow; spending plans can change it.
Financing items, sorted by what they do to the runway:
Extends the runway:
- The September raises ($596.5M net, including $48.7M of at-the-market sales) are already in the Sep 30 balance.
- Committed undrawn financing: none disclosed (the Q3 10-Q discloses no credit lines).
Shortens the runway:
- Convertible notes: $258.75M of 2.00% notes due Oct 15, 2032 (carried at $250.7M at Sep 30), with interest paid each Apr 15 and Oct 15 from Apr 15, 2027. Nothing falls due within 24 months (8-K, Q3 release).
- CordenPharma prepayments: announced as $150M in total, credited against future orders; the Q3 10-Q says they are paid over 2026–2028. The schedule and the amounts already paid are not disclosed, so they are not dated in the cash path.
Conditional:
- At-the-market programme: $449.8M of remaining gross capacity as of Sep 30, 2026 (10-Q Q3 2026). Uncommitted: it adds cash only if Viking chooses to sell shares.
- Buyback: $500M approved in July 2026; no purchases disclosed. Any purchase would use cash.
- Convertible-note repurchase right: holders can require repurchase at par if certain takeover or delisting events occur.
- Ligand milestones: up to about $1.54B in total under the licence, payable only if milestones are reached.
Cash path (our calculation; an illustration, not a forecast):
At the past rate and with known items, cash would fall below zero in Q4 2028 (Q1 2029 in our path from the Jun 30 balance); the company itself says its cash gives it the runway to complete its ongoing Phase 3 obesity trials, which it expects in 2027 (Q3 release), and it expects losses to increase materially.
Illustration, not a forecast.
- 1 · Q2 2027 · First note interest −$3M
- 2 · Q4 2027 · Note interest −$3M
- 3 · Q2 2028 · Note interest −$3M
- 4 · Q4 2028 · Note interest −$3M
Ending cash (cash, equivalents and marketable securities) Known item Raising window (under a year of usual spending left) Would need new money
| Quarter | Starting cash | Usual spending | Known items | Ending cash | Sources / notes |
|---|---|---|---|---|---|
| Q4 2026 | +959.8 | −115.7 | 0.0 | +844.1 | Starting cash at Sep 30, 2026, after the September raises (Q3 release) |
| Q1 2027 | +844.1 | −115.7 | 0.0 | +728.5 | |
| Q2 2027 | +728.5 | −115.7 | −2.9 | +609.9 | First note interest, Apr 15, 2027 (our calculation)12 |
| Q3 2027 | +609.9 | −115.7 | 0.0 | +494.3 | |
| Q4 2027 | +494.3 | −115.7 | −2.6 | +376.0 | Note interest, Oct 15 (our calculation)12. Less than a year of usual spending left. |
| Q1 2028 | +376.0 | −115.7 | 0.0 | +260.4 | Less than a year of usual spending left. |
| Q2 2028 | +260.4 | −115.7 | −2.6 | +142.1 | Note interest, Apr 15. Less than a year of usual spending left. |
| Q3 2028 | +142.1 | −115.7 | 0.0 | +26.4 | Less than a year of usual spending left. |
| Q4 2028 | +26.4 | −115.7 | −2.6 | −91.8 | Note interest, Oct 15 |
Amounts in $M.
Usual spending is an even quarter’s share of the past year’s free cash flow, about −$115.7M a quarter, held flat (our calculation)13.
No committed undrawn financing is disclosed, so there is no “financing that could extend the runway” table for Viking.
At the past rate and with known items, cash would fall below zero in Q4 2028 (Q1 2029 in our path from the Jun 30 balance); the company itself says its cash gives it the runway to complete its ongoing Phase 3 obesity trials, which it expects in 2027 (Q3 release), and it expects losses to increase materially. Our path assumes flat spending at the past rate. Companies usually raise money well before that; quarters with less than a year of usual spending left are shaded.
Known items in the path:
- From Q2 2027: interest on the convertible notes, about $2.6–2.9M each April and October.
- Not dated, so not included: the remaining CordenPharma prepayments ($150M in total, paid over 2026–2028 per the Q3 10-Q).
How we calculated this
Usual spending is TTM free cash flow (−$462.6M, Q4 2025–Q3 2026) divided by four, about −$115.7M a quarter (our calculation)13, held flat. Starting cash is cash, cash equivalents and short-term investments at Sep 30, 2026 ($959.8M). The September raises are already in that balance, so they are not known items. Known items are disclosed, dated amounts only. The note interest is a new contractual payment that past cash flow does not contain; the indenture requires interest to be calculated on a 360-day year of twelve 30-day months (supplemental indenture). The past year contains no one-off receipts or payments large enough to adjust for. Not included:
- CordenPharma prepayments: Viking announced prepayments totalling $150M, fully credited against future orders (release, Mar 11, 2025); the Q3 10-Q says they are paid over 2026–2028. The amounts already paid and the schedule by period are not disclosed, so we cannot date them; some may already be in past cash flow.
- Office lease payments (lease to Nov 7, 2031), under the no-double-counting rule: operating-lease payments are already inside usual spending.
- Capital spending: none reported in 2025 or the first nine months of 2026 and no disclosed plan.
- Changes in interest income or trial spending: historical interest income is embedded in usual spending; the path assumes no separate change in that income or in trial spending. Quarterly R&D expense over the past year ranged from $115.8M (Q2 2026) to $166.8M (Q3 2026), and the tablet Phase 3 trials started in Q4 2026.
- Ligand milestones (up to about $1.54B in total under the licence) and royalties: none dated.
- The convertible-note principal ($258.75M, due Oct 15, 2032), which falls outside the path.
6. Customer and contract exposure
Last updated Oct 28, 2026. Reflects the 10-K FY2025, the 10-Q Q2 2026 and the September 2026 offering documents.
Viking has no revenue and therefore no customers, distributors or government sales. Its exposure is to the contracts that supply, license and fund its drugs. In short: one supplier makes VK2735 and is paid in advance ($150M of prepayments), a licensor could be owed up to about $1.54B in milestones and is in a court dispute with Viking, and $258.75M of convertible notes are due in 2032.
Contracts and counterparties
- CordenPharma (supplier), multi-year agreements signed Mar 10, 2025 for VK2735:
- Capacity: dedicated capacity for multiple metric tons of active ingredient a year, an annual commitment to supply 100 million autoinjectors plus 100 million vials and syringes, and annual capacity of over one billion tablets, all expandable at Viking’s option.
- Money: Viking makes prepayments totalling $150M over 2025–2028, credited against future orders (release, Mar 11, 2025; the 10-Q describes the remaining prepayments as payable over 2026–2028). The 10-Q lists CordenPharma’s ability to achieve its prepayment milestones as a risk.
- Term: an initial eight-year term from Mar 10, 2025, renewing automatically for successive three-year terms unless notice is given (notice periods are redacted). Viking may terminate at will after the initial term; either side may terminate for uncured material breach, and Viking may terminate after a regulatory failure (agreement, Article 14, filed Apr 24, 2025).
- Ligand (licensor):
- Under the 2014 Master License Agreement, Viking may owe Ligand up to about $1.54B in development, regulatory and sales milestones and single-digit royalties on sales of licensed products. VK2735 and VK3019 are Viking’s own and are not covered.
- Ligand notified Viking on Apr 24, 2026 that it purported to terminate the TR-β licence (VK2809, VK0214), effective May 4, 2026; Viking disputes the termination. Ligand sued on May 19, 2026, seeking damages and the return of certain intellectual property. Viking’s cross-complaint of Jul 2, 2026 seeks a declaration that it did not breach the agreement (10-Q Q2 2026). On Aug 19, 2026, Ligand and Metabasis filed a demurrer seeking dismissal of Viking’s cross-claims for breach of contract and of the implied covenant of good faith; Viking will oppose it (due Feb 11, 2027), the hearing is set for Feb 26, 2027, and written discovery has begun (10-Q Q3 2026).
- Ascletis (litigation; possible gain): Viking won a trade-secrets ruling at the US International Trade Commission, including monetary and non-monetary sanctions, affirmed on May 29, 2025. Both sides have appealed to the Federal Circuit; Viking filed its responsive brief on Sep 25, 2026 and oral argument is expected in Q4 2027. A related federal court case in San Diego is pending (10-Q Q3 2026).
- Convertible noteholders: $258.75M of senior unsecured notes, 2.00% interest, due Oct 15, 2032; conversion price about $50.75. Viking can redeem them from Oct 22, 2029 if the share price exceeds 130% of the conversion price for 20 of 30 trading days; holders can require repurchase at par on certain takeover or delisting events (8-K).
- Office lease: one operating lease in San Diego, amended from Apr 8, 2026 and running to Nov 7, 2031, with a five-year renewal option (10-Q Q2 2026, lease note).
7. What to watch
Last updated Oct 29, 2026. Reflects the 10-Q Q3 2026, the September 2026 offering documents and company releases through Oct 28, 2026.
| Date | Item | Source |
|---|---|---|
| Nov 14–15, 2026 | Two VK2735 posters at ObesityWeek (VANQUISH-2 baseline characteristics; VENTURE cardiometabolic results) | Q3 release |
| Nov 2026 | Expected first patients in the SUNRISE-1 and SUNRISE-2 tablet trials | ClinicalTrials.gov NCT07868835, NCT07868939 |
| Dec 31, 2026 | Latest scheduled end of the CEO’s trading plan, adopted Jan 15, 2026, covering up to 365,000 shares; it ends earlier if all covered shares are sold | 10-Q Q1 2026, Part II, Item 5 |
| Q4 2026 | Completion of the VK3019 single-dose Phase 1 study | Q3 release |
| Feb 11 and Feb 26, 2027 | Ligand case: Viking’s opposition to the demurrer against its cross-claims is due (Feb 11); hearing on the demurrer (Feb 26) | 10-Q Q3 2026, Legal Proceedings |
| Q1 2027 | Start of the VANQUISH extension studies (up to 52 more weeks, including every-other-week and monthly dosing) and of a 4-week multiple-dose VK3019 study | Q3 release |
| 2027 (registry: May 2027) | Results of Part 2 of the maintenance study (tablet and injection maintenance regimens, about 195 adults) | Release, Oct 6; ClinicalTrials.gov NCT07838740 |
| 2027 (registry: Jul 1, 2027, estimated) | Completion of VANQUISH-1 and VANQUISH-2 (78-week weight loss vs placebo), which Viking expects in 2027 | Q3 release; ClinicalTrials.gov NCT07104500, NCT07104383 |
| Q4 2027 | Federal Circuit oral argument in the Ascletis appeal (expected) | 10-Q Q3 2026, Legal Proceedings |
| Dec 7, 2027 | Latest end of director Charles Rowland’s trading plan (adopted Sep 4, 2026; up to 128,000 shares) | 10-Q Q3 2026, Part II, Item 5 |
| 2028 | Results of the VANQUISH extension studies | Q3 release |
| Jul and Oct 2028 (estimated) | Primary completion of SUNRISE-1 and SUNRISE-2 (68 weeks) | ClinicalTrials.gov NCT07868835, NCT07868939 |
Additional dates
| Date | Item | Source |
|---|---|---|
| No date disclosed | Ligand lawsuit over the TR-β licence; Federal Circuit appeal in the Ascletis case | 10-Q Q2 2026 |
Valuation at each update
| Update | Close | Market value | EV | P/S | EV/sales | P/E | P/FCF | Revenue growth | FCF margin | Net cash (debt) | Basis |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | $24.89 (Oct 27) | $2.9B | $2.4B | n/m | n/m | n/m | n/m | n/m | n/m | $502M | 12 months to Jun 30, 2026; pre-revenue |
| Oct 29, 2026 | $25.36 (Oct 28) | $3.2B | $2.5B | n/m | n/m | n/m | n/m | n/m | n/m | $709M | 12 months to Sep 30, 2026; pre-revenue |
Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Oct 29, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 28, 2026 price: the Long View's stated close (Yahoo Finance; matches Nasdaq). Oct 29, 2026 price: official close, Nasdaq historical quotes.
Notes and calculations
Section sources:
- Section 1: 10-K FY2025 (business, employees, statements of operations); 10-Q Q2 2026; Q2 release (“wholly owned”); Oct 14 release.
- Section 3: Q3 release, Q2 release, Q4 2025 release, 10-Q Q1 2026, 10-Q Q2 2026, maintenance release, Oct 14 release, ClinicalTrials.gov NCT07868835.
- Section 4 (stock-based pay): 10-K FY2022 (2022) and 10-K FY2025 (2023–2025) cash flow statements; 10-Q Q2 2026.
- Section 5 (profit vs cash): 10-K FY2025 and 10-Q Q2 2026 cash flow statements.
-
7,441,650 shares × $85.00 = $632.5M gross. ↩
-
Q2 operating cash use = H1 2026 $239.148M − Q1 2026 $113.976M = $125.172M, rounded to $125.2M (10-Q Q1 2026, 10-Q Q2 2026 cash flow statements). ↩
-
Q3 2026 operating cash use = 9M 2026 $377.342M − H1 2026 $239.148M = $138.194M, rounded to $138.2M (10-Q Q3 2026, 10-Q Q2 2026 cash flow statements); our provisional estimate before the 10-Q was $137.8M. No capital spending. ↩ ↩2
-
Shares outstanding 78.248M (Dec 31, 2021) and 127.521M (Sep 30, 2026, Q3 release). Growth = (127.521 ÷ 78.248 − 1) × 100 ≈ 63%; annual growth = [(127.521 ÷ 78.248)^(1 ÷ 4.75) − 1] × 100 ≈ 10.8%; remaining ownership = 1% × 78.248 ÷ 127.521 ≈ 0.61%; buyback offset = 2.19M shares repurchased ÷ 52.7M shares issued gross (before shares withheld for taxes) ≈ 4%. ↩
-
Chart source: chart values are the rows of the share bridge in section 4 (millions of shares); “Stock pay and warrants” adds the stock-pay and warrant rows (2022: 0.3 + 0.5 = 0.8). Buybacks (−2.2M in 2022) are not charted. ↩
-
Q3 2026 share bridge (10-Q equity statement): 116.653M (Jun 30) + 10.512M shares sold (1.477M at-the-market and 9.036M offering shares) + 0.356M under employee stock plans (including 0.285M vested performance units) = 127.521M (Sep 30). Shares on conversion of the notes: $258.75M ÷ $1,000 × 19.7044 ≈ 5.10M. ↩ ↩2
-
Average price = gross proceeds ÷ shares, using unrounded share counts. 2022 buyback: $6.795M ÷ 2.193M shares ≈ $3.10. 2024 underwritten: 7,441,650 × $85.00 = $632.5M. Viking reports at-the-market proceeds net of fees, so gross at-the-market proceeds are approximated from changes in the disclosed remaining programme capacity, which is rounded: 2024, $200.0M − $151.9M ≈ $48.1M (remaining capacity per the 10-K FY2024); 2025, $151.9M − $75.7M ≈ $76.2M; H1 2026, $75.7M − $40.4M ≈ $35.3M; Aug–Sep 2026, $500.0M new programme − $449.8M remaining ≈ $50.2M. 2024: ($632.5M + $48.1M) ÷ 8.868M ≈ $76.75. 2025: $76.2M ÷ 2.131M ≈ $35.76. 2026 to date: ($35.3M + $50.2M + $316.25M) ÷ 11.547M ≈ $34.79. ↩ ↩2 ↩3 ↩4 ↩5
-
Stock-based compensation ÷ operating expenses × 100 (2022 operating expenses from the 10-K FY2022; later years from the 10-K FY2025 and 10-Q Q2 2026). ↩
-
TTM = FY2025 − 9M 2025 + 9M 2026: net loss −$359.6M + $202.0M − $469.5M = −$627.2M; operating cash flow −$278.7M + $193.4M − $377.3M = −$462.6M; stock pay $40.8M − $32.2M + $39.4M = $47.9M (10-Q Q3 2026). Free cash flow = operating cash flow minus capital spending (none reported). ↩ ↩2 ↩3
-
Runway = $959.8M ÷ $462.6M ≈ 2.1 years (about 8 quarters). Based on past cash flow; spending plans can change it. On the Jun 30 balance it was $501.7M ÷ $418.4M ≈ 1.2 years before the September raises. ↩
-
Trailing 12 months to Sep 30, 2026. Free cash flow = Q4 2025 (FY2025 −$278.7M − 9M 2025 −$193.4M = −$85.3M; 10-Q Q3 2025) + 9M 2026 −$377.3M (10-Q Q3 2026) ≈ −$462.6M. Net loss = FY2025 −$359.6M − 9M 2025 −$202.0M + 9M 2026 −$469.5M = −$627.2M. The Q3 2026 dilution row is from the share bridge in note 10 (employee stock plans 0.356M ≈ 0.4M). ↩
-
First coupon, Apr 15, 2027: $258.75M × 2.00% × 200 ÷ 360 ≈ $2.9M (interest from Sep 25, 2026 on a 30/360 basis, as the indenture requires); later semi-annual coupons: $258.75M × 1.00% ≈ $2.6M. ↩ ↩2
-
−$462.6M ÷ 4 ≈ −$115.7M a quarter (−$418.4M ÷ 4 ≈ −$104.6M on the Jun 30 basis). ↩ ↩2
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.
About Viking Therapeutics: Website (external site)Investor relations (external site)SEC filings (external site)